Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

Lagar i iiii	9. 1121 1100 111211/11 201100 1140	1 01111 0 11
REPROS THERAPEUTICS INC.		
Form 8-K		
December 19, 2016		
THE STATE OF LAND		
UNITED STATES		
SECURITIES AND EXCHANGE CO	OMMISSION	
Washington, D.C. 20549		
Form 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of the	e Securities Exchange Act of 1934	
Date of Report	(Date of earliest event Reported): Dece	ember 19-2016
Date of Report	(Date of earnest event Reported). Deed	51110C1 17, 2010
	Repros Therapeutics Inc.	
(Exac	et Name of Registrant as Specified in C	harter)
Delaware	001-15281	76-0233274
(State or Other Jurisdiction of	(Commission File Number)	· • •
Incorporation)		Number)
2408 Timberloch Place, Suite B-7,	The Woodlands.	
Texas 77380		
(Address of Principal Executive Off	rices) (Zip Code)	
- -	(281) 719-3400	
(Regis	trant's telephone number, including are	a code)
(Former no	ume or former address, if changed since	last report)
(Former its	une of former address, if changed since	rast report)
Check the appropriate box below if the the registrant under any of the following		neously satisfy the filing obligation of
-	o Rule 425 under the Securities Act (17	CFR 230.425)
Soliciting material pursuant to Rule	14a-12 under the Exchange Act (17 C	FR 240.14a-12)
Pre-commencement communication	ns pursuant to Rule 14d-2(b) under the	Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

Item 7.01. Regulation FD Disclosure.

On December 19, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated December 19, 2016

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repros Therapeutics Inc.

Date: December 19, 2016

By: /s/ Kathi Anderson

Kathi Anderson

CFO